Gregory P Bisson, MD, MSCE
Assistant Professor of Medicine
Department: Medicine
Graduate Group Affiliations
Contact information
836 Blockley Hall
423 Guardian Drive
Center for Clinical Epidemiology and Biostatistics
University of Pennsylvania
Philadelphia, PA 19104-6021
423 Guardian Drive
Center for Clinical Epidemiology and Biostatistics
University of Pennsylvania
Philadelphia, PA 19104-6021
Office: 215-573-5811
Fax: 215-573-5315
Fax: 215-573-5315
Email:
bisson@mail.med.upenn.edu
bisson@mail.med.upenn.edu
Education:
BA (Japanese)
University of Wisconsin-Madison, 1992.
MD
University of Minnesota School of Medicine, 1997.
MSCE
Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, School of Medicine, 2006.
Permanent linkBA (Japanese)
University of Wisconsin-Madison, 1992.
MD
University of Minnesota School of Medicine, 1997.
MSCE
Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, School of Medicine, 2006.
Description of Research Expertise
Pursuing clinically important research questions in the area of Human Immunodeficiency Virus (HIV) infection, focusing primarily on the application of epidemiologic methods to the study of the natural history and treatment of clincally important viral and fungal co-infectios as well as on the design of creative public health approaches to the rapid delivery, or scale-up, of highly active antiretroviral therapy (HAART) in the developing world.Selected Publications
Vinnard C, Winston CA, Wileyto EP, Macgregor RR, Bisson GP: Multidrug Resistant Tuberculous Meningitis in the United States, 1993-2005. Journal of Infection 2011 doi:10.1016/j.jinf.2011.07.005.Vinnard C, Winston CA, Wileyto EP, MacGregor RR, Bisson GP.: Isoniazid-resistant tuberculous meningitis, United States, 1993-2005. Emerg Infect Dis.(3), 539-42, March 2011.
Steele K, Steenhoff A, Newcomb C, Rantleru T, Nthobatsang R, Lesetedi G, Bellamy S, Nachega J, Gross R, Bisson GP.: Early Mortality and AIDS Progression Despite High Initial Antiretroviral Therapy Adherence and Virologic Suppression in Botswana". PLoS ONE 6(6), 2011.
Vinnard C, Winston C, Wileyto P, Macgregor RR, Bisson GP.: Factors Associated with Isoniazid Resistant Tuberculous Meningitis in the United States, 1993 to 2005, Mar; [Epub ahead of print] Emerging Infectious Diseases, 2011.
Ahmad Z, Fraig MM, Bisson GP, Nuermberger EL, Grosset JH, Karakousis PC.: Dose-dependent activity of pyrazinamide in animal models of intracellular and extracellular tuberculosis infections. Antimicrob Agents Chemother.(4), 1527-32, 2011.
Vinnard C, Winston C, Wileyto P, MacGregor RR, and Bisson GP: Isoniazid Resistance and Death in Patients with Tuberculous Meningitis: A Retrospective Cohort Study. British Medical Journal 6: 341:c4451, Sep 2010.
Simbiri K, Murakami M, Feldman M, Steenhoff A, Nkomazana O, Bisson GP, and Robertson E: Multiple Oncogenic Viruses Identified in Ocular Surface Squamous Neoplasia in HIV-1 patients. Infectious Agents and Cancer 5:6doi:10.1186/1750-9378: 5-6, 2010.
Steele K, Thakur R, Nthobatsang R, Steenhoff A, Bisson GP : In-hospital mortality of HIV-infected cryptococcal meningitis patients with C. gattii and C. neoformans infection in Gaborone, Botswana. Medical Mycology Page: 1-4, 2010.
Gross R, Aplenc R, TenHave T, Foulkes A, Thakur R, Mosepele M, Barrett J, Flexner C, Strom B, Bisson GP: Slow Efavirenz Metabolism Genotype is Common in Botswana. JAIDS 49(3): 336-337, November 2008.
Bisson GP, Nthobatsong R, Thakur R, Lesetedi G, Vinekar K, Tebas P, Gluckman S, Gaolathe T, MacGregor R.: The use of HAART is associated with decreased risk of death during initial treatment of Cryptococcal meningitis in HIV-infected adults in Botswana. JAIDS 49(2): 227-229, October 2008.